Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Spaulding Clinical Research LLC | OTHER |
Not provided
Not provided
Not provided
Not provided
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with lower CBD doses with unapproved consumer products highlights a need for further research. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.
The objective of this study is to characterize the effects of daily CBD use at a dose within the range of what consumers are taking as unapproved CBD products on liver enzyme elevations, drug interactions, and endocrine measures.
The cannabis plant contains bioactive compounds known as cannabinoids; delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent cannabinoids in most varieties of cannabis. The Agricultural Improvement Act (Farm Bill) of 2018 removed hemp, defined as cannabis and derivatives of cannabis with extremely low concentrations of THC, from the definition of marijuana in the Controlled Substances Act. Following this, many CBD products have been made available to consumers. However, hemp products remain subject to regulation under the Federal Food Drug & Cosmetic Act, when applicable (e.g., as drugs, foods, dietary supplements, cosmetics, veterinary products) and the growing CBD products market raises various safety concerns, especially with long-term use.
CBD is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with CBD doses in unapproved consumer products highlights a need for further research to quantify risks at these doses. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.
This study will be divided into two parts.
In Part 1, 200 healthy subjects will be randomized to 5 mg/kg/day of CBD (150 subjects) or placebo (50 subjects) for 4 weeks with weekly laboratory assessments to characterize the percentage of participants with liver enzyme elevation (primary endpoint) or meeting withdrawal criteria for potential drug-induced liver injury (secondary endpoint). Additional secondary endpoints include the change from baseline after 4 weeks of daily CBD dosing for male reproductive (testosterone and inhibin B) and thyroid hormones (thyroid stimulating hormone [TSH], triiodothyronine [T3] and thyroxine [T4]) as secondary endpoints. Exploratory endpoints include additional characterization of liver findings and other blood biomarkers.
In Part 2, 40 healthy subjects will receive either oral citalopram (20 subjects) or morphine (20 subjects) at baseline and then again after receiving CBD 5 mg/kg/day to characterize the effect of daily cannabidiol use on the plasma concentration of citalopram and morphine. Citalopram was selected because it is a common prescription medication for depression and anxiety that is metabolized by CYP2C19 and CYP3A4, which CBD inhibits. Morphine was selected because it is a common opioid analgesic that is metabolized by UGT2B7, which CBD inhibits.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cannabidiol (Part 1) | Active Comparator | Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days. |
|
| Placebo (Part 1) | Placebo Comparator | Subjects in this arm will receive oral solution placebo twice a day for 28 days. |
|
| Cannabidiol and Citalopram Drug Interaction (Part 2) | Active Comparator | Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17). |
|
| Cannabidiol and Morphine Drug Interaction (Part 2) | Active Comparator | Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cannabidiol | Drug | Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN). | The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females. | Days 1 through 35 |
| Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing. | 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13) |
| Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing. | 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13) |
| Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing. |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI). | Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria.
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Abnormal liver labs at screening on check-in (Day -1), defined as any of the following (tests may be repeated once for confirmation at screening and check-in):
Use or intend to use any medications/products in the 14 days prior to check-in (Day -1), unless deemed acceptable by the investigator
Subject is currently participating in another clinical study of an investigational drug or has been treated with any investigational drug within 30 days or 5 half-lives (whichever is longer) of dosing for this study.
Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, electronic cigarettes) within 6 weeks of Screening. Subjects must refrain from using these throughout the study.
Subject has consumed alcohol, xanthine-containing products (e.g., tea, coffee, chocolate, cola), caffeine, kava melatonin, St Johns Wart, grapefruit, or grapefruit juice within 24 hours of check-in. Subjects must refrain from ingesting these throughout the study.
Subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points (e.g., before and during CBD dosing).
Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months before Screening, has a history of alcoholism or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor)
Subject has a positive test result for alcohol or drugs of misuse (amphetamines, barbiturates, benzodiazepines, cocaine, alcohol, opiates, phencyclidine, propoxyphene, and methadone) at Screening or Check-in (Day -1 [both Parts]; Day 10 [Part 2, morphine DDI]; Day 12 [Part 2, citalopram DDI]).
Subject has a positive test result for cannabinoids (THC) at screening or Day -1.
Subject has a history of opioid or narcotic misuse.
Subject has a history of suicidal ideation or previous suicide attempts
Subject has a history or evidence of a clinically significant disorder, condition, or disease (e.g., cancer, human immunodeficiency virus [HIV], hepatic or renal impairment) that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
Subject has any signs or symptoms that are consistent with Coronavirus Disease 2019 (COVID-19) per Center for Disease Control (CDC) recommendations at screening or check-in (Day -1). These include subjects with fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea may have COVID-19. In addition, the subject has any other findings suggestive of COVID-19 risk in the opinion of the investigator.
Subject has known or suspected allergies or sensitivities to the study drug or placebo components (e.g., sucralose, sesame).
Subjects with a documented hypersensitivity reaction to cannabidiol
Subjects with a documented medical history of clinical disorders related to mood, anxiety or panic, including diagnosed depression, generalized anxiety disorder or panic attacks.
Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome). Uncomplicated cholecystectomies and appendectomies may be included at the investigator's discretion.
Subject has clinical laboratory test results (hematology, serum chemistry and urinalysis) at Screening or Check-In that are outside the reference ranges provided by the clinical laboratory and considered clinically significant by the investigator. Tests may be repeated once for confirmation at both Screening and Check-In.
Subject has a positive test result at Screening for HIV 1 or 2 antibody, hepatitis C virus antibodies, or hepatitis B surface antigen.
Subject has a mean systolic blood pressure <85 or >145 mmHg or a mean diastolic blood pressure <45 or >95 mmHg at either Screening or Check-in. Blood pressure will be measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.
Subject is unable or unwilling to undergo multiple venipunctures for blood sample collection because of poor tolerability or is unlikely to complete the study due to poor venous access.
Female subject is currently pregnant or lactating or was within 3 months of the study.
Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before Check-in.
Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Melanie Fein, MD | Spaulding Clinical Research LLC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Spaulding Clinical Research | West Bend | Wisconsin | 53095 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | 1. U.S. Food and Drug Administration (FDA) Science Board. (2022, June 3). Background materials for the June 14, 2022 meeting of the Science Board to the FDA. Retrieved from https://www.fda.gov/advisory-committees/advisory-committee-roster/science-board-fda/2022-meetings#event-materials. | ||
| Background | 2. Cannabidiol (Epidiolex ®) oral solution label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf | ||
| 36912195 | Background | Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023 Jun;293(6):724-752. doi: 10.1111/joim.13627. Epub 2023 Mar 13. | |
| 34387679 |
Not provided
Not provided
Plan is to make data from the study publicly available as part of a manuscript publication. In addition, the protocol and statistical analysis plan will be made available online at this site as well as with any eventual publications.
The data will become available at the time of manuscript publication.
No restrictions.
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cannabidiol (Part 1) | Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days. Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. |
| FG001 | Placebo (Part 1) | Subjects in this arm will receive oral solution placebo twice a day for 28 days. Placebo: Placebo will be administered orally twice daily for 28 days in Part 1 |
| FG002 | Cannabidiol and Citalopram Drug Interaction (Part 2) | Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17). Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. Citalopram: Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13. |
| FG003 | Cannabidiol and Morphine Drug Interaction (Part 2) | Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12). Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. Morphine: Morphine will be administered once at 15 mg on days 1, 4, and 11. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cannabidiol (Part 1) | Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days. Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN). | The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females. | The liver safety analysis population will include all subjects who receive at least 1 dose of the study drug and have at least one on-treatment liver and hematology lab assessment. Subjects in the liver safety analysis population will be used for the planned primary, secondary, and exploratory analyses related to liver enzyme elevations and liver events. Results will be reported as percentages with a 95% confidence interval (CI) based on a Kaplan-Meier analysis. | Posted | Number | 95% Confidence Interval | percentage of participants | Days 1 through 35 |
|
Part 1: 36 days Part 2: 24 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cannabidiol (Part 1) | Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days. Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anxiety | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jeffry Florian | U.S. Food and Drug Administration | 301-796-4847 | Jeffry.Florian@fda.hhs.gov |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 19, 2024 | Dec 11, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 8, 2024 | Dec 11, 2024 | SAP_001.pdf |
| ICF | No | No | Yes | Informed Consent Form | May 10, 2024 | Dec 11, 2024 | ICF_002.pdf |
Not provided
| ID | Term |
|---|---|
| D056486 | Chemical and Drug Induced Liver Injury |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D002185 | Cannabidiol |
| D015283 | Citalopram |
| D009020 | Morphine |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided
This is a two-part study. Part 1 is a randomized, double-blind, placebo-controlled, parallel study in 200 subjects (150 subjects receiving cannabidiol and 50 subjects receiving placebo).
Part 2 is an open-label, sequential study in 40 subjects (two separate cohorts of 20 subjects).
Not provided
Not provided
Part 1 of the study will be double-blind, and the blind will be maintained through a randomization schedule held by the dispensing pharmacist. The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.
Part 2 is an open label study.
|
| Placebo | Drug | Placebo will be administered orally twice daily for 28 days in Part 1 |
|
| Citalopram | Drug | Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13. |
|
|
| Morphine | Drug | Morphine will be administered once at 15 mg on days 1, 4, and 11. |
|
| 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
| Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing. | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
| Days 1 through 35 |
| Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Days 1 and 29 |
| Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Days 1 and 29 |
| Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Days 1 and 29 |
| Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Days 1 and 29 |
| Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Days 1 and 29 |
| Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing. | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
| Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing. | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
| Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing. | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
| Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing. | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
| Background |
| Crippa JAS, Zuardi AW, Guimaraes FS, Campos AC, de Lima Osorio F, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Pereira-Lima K, Sen S, Andraus MH, Hallak JEC; Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. doi: 10.1001/jamanetworkopen.2021.20603. |
| Background | 5. U.S. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf |
| Background | 6. EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck, D, Bohn, T, Castenmiller, J, De Henauw, S, Hirsch-Ernst, KI, Maciuk, A, Mangelsdorf, I, McArdle, HJ, Naska, A, Pelaez, C, Pentieva, K, Siani, A, Thies, F, Tsabouri, S, Vinceti, M, Cubadda, F, Frenzel, T, Heinonen, M, Marchelli, R, Neuhäuser-Berthold, M, Poulsen, M, Prieto Maradona, M, Schlatter, JR, Trezza, V, van Loveren, H, Albert, O, Dumas, C, Germini, A, Gelbmann, W, Kass, G, Kouloura, E, Noriega Fernandez, E, Rossi, A and Knutsen, HK, 2022. Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA Journal 2022; 20(6):7322, 25 pp. https://doi.org/10.2903/j.efsa.2022.7322 |
| 31313338 | Background | Carvalho RK, Andersen ML, Mazaro-Costa R. The effects of cannabidiol on male reproductive system: A literature review. J Appl Toxicol. 2020 Jan;40(1):132-150. doi: 10.1002/jat.3831. Epub 2019 Jul 17. |
| 37734651 | Background | Tallon MJ, Child R. Subchronic oral toxicity assessment of a cannabis extract. Regul Toxicol Pharmacol. 2023 Oct;144:105496. doi: 10.1016/j.yrtph.2023.105496. Epub 2023 Sep 19. |
| 34121064 | Background | Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, Amminger GP, McGregor IS. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):525-533. doi: 10.1097/JCP.0000000000001427. |
| 12618536 | Background | Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics. 2003 Mar-Apr;44(2):167-71. doi: 10.1176/appi.psy.44.2.167. |
| Background | 11. Citalopram (Celexa ®) tablet label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf |
| Background | 12. Morphine Sulfate tablet label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022207s010lbl.pdf |
| 34093420 | Background | Iannone LF, Arena G, Battaglia D, Bisulli F, Bonanni P, Boni A, Canevini MP, Cantalupo G, Cesaroni E, Contin M, Coppola A, Cordelli DM, Cricchiuti G, De Giorgis V, De Leva MF, De Rinaldis M, d'Orsi G, Elia M, Galimberti CA, Morano A, Granata T, Guerrini R, Lodi MAM, La Neve A, Marchese F, Masnada S, Michelucci R, Nosadini M, Pilolli N, Pruna D, Ragona F, Rosati A, Santucci M, Spalice A, Pietrafusa N, Striano P, Tartara E, Tassi L, Papa A, Zucca C, Russo E, Mecarelli O; CBD LICE Italy Study Group. Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Front Neurol. 2021 May 20;12:673135. doi: 10.3389/fneur.2021.673135. eCollection 2021. |
| Background | 14. Sharbaf Shoar N, Fariba KA, Padhy RK. Citalopram. StatPearls https://www.ncbi.nlm.nih.gov/books/NBK482222/ |
| 21544079 | Background | Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58. Epub 2011 May 4. |
| 36259271 | Background | Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci. 2023 Jan;16(1):10-30. doi: 10.1111/cts.13425. Epub 2022 Oct 19. |
| 40622698 | Derived | Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, Patel V, Yang S, Fein M, DePalma R, Matta M, Strauss DG, Rouse R. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 1;185(9):1070-1078. doi: 10.1001/jamainternmed.2025.2366. |
| BG001 | Placebo (Part 1) | Subjects in this arm will receive oral solution placebo twice a day for 28 days. Placebo: Placebo will be administered orally twice daily for 28 days in Part 1 |
| BG002 | Citalopram and Cannabidiol (Part 2) | Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17). Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. Citalopram: Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13. |
| BG003 | Morphine and Cannabidiol (Part 2) | Subjects in this arm will receive morphine (15 mg) on Day 1 (baseline), Day 4, and Day 11 (with CBD). Oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 9 days (Day 4-12). Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. Morphine: Morphine sulfate tablet will be administered once at 15 mg on days 1, 4 and 11. |
| BG004 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Median Body Weight | Median | Full Range | kg |
|
| Median Height | Median | Full Range | m |
|
| Median Body Mass Index | Median | Full Range | kg/m2 |
|
| Cannabidiol (Part 1) |
Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days. Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. |
| OG001 | Placebo (Part 1) | Subjects in this arm will receive oral solution placebo twice a day for 28 days. Placebo: Placebo will be administered orally twice daily for 28 days in Part 1 |
|
|
| Primary | Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. One subject was removed from the analysis due to a protocol violation. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13) |
|
|
|
|
| Primary | Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. One subject was removed from the analysis due to a protocol violation. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13) |
|
|
|
|
| Primary | Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. For morphine and its metabolites, number of subjects is 20 for morphine alone and morphine with a single dose of CBD. For morphine with multiple doses of CBD, the sample size is 18 as two subjects discontinued from the study. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
|
|
|
|
| Primary | Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. For morphine and its metabolites, number of subjects is 20 for morphine alone and morphine with a single dose of CBD. For morphine with multiple doses of CBD, the sample size is 18 as two subjects discontinued from the study. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
|
|
|
|
| Secondary | Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI). | Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria.
| The liver safety analysis population will include all subjects who receive at least 1 dose of the study drug and have at least one on-treatment liver and hematology lab assessment. Subjects in the liver safety analysis population will be used for the planned primary, secondary, and exploratory analyses related to liver enzyme elevations and liver events. Results will be reported as percentages with a 95% confidence interval (CI) based on a Kaplan-Meier analysis. | Posted | Number | 95% Confidence Interval | percentage of participants | Days 1 through 35 |
|
|
|
| Secondary | Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Analyses include male participants with time-matched samples at day 1 and 29 | Posted | Least Squares Mean | 95% Confidence Interval | ng/dL | Days 1 and 29 |
|
|
|
| Secondary | Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Analyses include male participants with time-matched samples at day 1 and 29 | Posted | Least Squares Mean | 95% Confidence Interval | pg/mL | Days 1 and 29 |
|
|
|
| Secondary | Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Analyses include all participants with time-matched samples at day 1 and 29. Participants without day 29 samples (e.g., discontinued treatment prior to day 29) were excluded from the analysis. | Posted | Least Squares Mean | 95% Confidence Interval | mU/mL | Days 1 and 29 |
|
|
|
| Secondary | Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Analyses include all participants with time-matched samples at day 1 and 29. Participants without day 29 samples (e.g., discontinued treatment prior to day 29) were excluded from the analysis. | Posted | Least Squares Mean | 95% Confidence Interval | ng/mL | Days 1 and 29 |
|
|
|
| Secondary | Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo. | Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group. | Analyses include all participants with time-matched samples at day 1 and 29. Participants without day 29 samples (e.g., discontinued treatment prior to day 29) were excluded from the analysis. | Posted | Least Squares Mean | 95% Confidence Interval | ng/mL | Days 1 and 29 |
|
|
|
| Secondary | Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. For morphine and its metabolites, number of subjects is 20 for morphine alone and morphine with a single dose of CBD. For morphine with multiple doses of CBD, the sample size is 18 as two subjects discontinued from the study. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
|
|
|
|
| Secondary | Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. For morphine and its metabolites, number of subjects is 20 for morphine alone and morphine with a single dose of CBD. For morphine with multiple doses of CBD, the sample size is 18 as two subjects discontinued from the study. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
|
|
|
|
| Secondary | Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. For morphine and its metabolites, number of subjects is 20 for morphine alone and morphine with a single dose of CBD. For morphine with multiple doses of CBD, the sample size is 18 as two subjects discontinued from the study. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
|
|
|
|
| Secondary | Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing. | All subjects who receive at least one dose of study drug and have at least one on-treatment PK sample collected. For morphine and its metabolites, number of subjects is 20 for morphine alone and morphine with a single dose of CBD. For morphine with multiple doses of CBD, the sample size is 18 as two subjects discontinued from the study. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11) |
|
|
|
|
| 0 |
| 151 |
| 0 |
| 151 |
| 43 |
| 151 |
| EG001 | Placebo (Part 1) | Subjects in this arm will receive oral solution placebo twice a day for 28 days. Placebo: Placebo will be administered orally twice daily for 28 days in Part 1 | 0 | 50 | 0 | 50 | 9 | 50 |
| EG002 | Cannabidiol and Citalopram Drug Interaction (Part 2) | Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17). Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. Citalopram: Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13. | 0 | 20 | 0 | 20 | 7 | 20 |
| EG003 | Cannabidiol and Morphine Drug Interaction (Part 2) | Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12). Cannabidiol: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2. Morphine: Morphine will be administered once at 15 mg on days 1, 4, and 11. | 0 | 20 | 0 | 20 | 5 | 20 |
| Application Site Irritation | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Arthropod Bite | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Back Pain | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Bacterial Vaginosis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Dry Mouth | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Eosinophilia | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Epigastric Discomfort | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Epistaxis | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Flatulence | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Headache | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Hepatic Enzyme Increase | Hepatobiliary disorders | MedDRA 23.0 | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment |
|
| Lymphadenopathy Cervical | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Muscle Weakness | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Nasal Congestion | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Nightmares | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Somnolence | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Sunburn | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Toothache | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Urine Odor Foul | Renal and urinary disorders | MedDRA 23.0 | Systematic Assessment |
|
| Urogenital Trichomoniasis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Venipuncture Site Hematoma | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
|
| Viral Syndrome | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Abdominal Pain | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Bloating | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Distention | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Feeling Hot | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Presyncope | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Pruritis | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Skin Abrasion | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Thermal Burn | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Abrasion | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
| Bronchitis | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| COVID-19 serology test positive | Investigations | MedDRA 23.0 | Systematic Assessment |
|
| Decreased Appetite | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Non-sustained ventricular tachycardia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
|
| Vasovagal reaction | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
Not provided
Not provided
| D011041 | Poisoning |
| D011437 |
| Propylamines |
| D000588 | Amines |
| D009570 | Nitriles |
| D001572 | Benzofurans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| Area under the curve was log-transformed and the values between groups were compared using a linear mixed effects model with group as a categorical variable and subject as a random effect. | Mixed Models Analysis | Analyses are not adjusted for multiplicity. | 0.10 | Geometric mean ratio | 1.12 | 2-Sided | 90 | 1.00 | 1.26 | Comparison was the effect of a multiple doses of cannabidiol on morphine compared to morphine alone. | Other | A difference in exposure was concluded if the 2-sided 90% CI of the geometric mean ratio excluded 1, which is standard in pharmacokinetic studies |
| Maximum concentration was log-transformed and the values between groups were compared using a linear mixed effects model with group as a categorical variable and subject as a random effect | Mixed Models Analysis | Analyses are not adjusted for multiplicity. | 0.29 | Geometric mean ratio | 1.11 | 2-Sided | 90 | 0.94 | 1.30 | Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone. | Other | A difference in exposure was concluded if the 2-sided 90% CI of the geometric mean ratio excluded 1, which is standard in pharmacokinetic studies |
| Area under the curve was log-transformed and the values between groups were compared using a linear mixed effects model with group as a categorical variable and subject as a random effect | Mixed Models Analysis | Analyses are not adjusted for multiplicity. | 0.73 | Geometric mean ratio | 0.99 | 2-Sided | 90 | 0.96 | 1.03 | Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone. | Other | A difference in exposure was concluded if the 2-sided 90% CI of the geometric mean ratio excluded 1, which is standard in pharmacokinetic studies |
| Maximum concentration was log-transformed and the values between groups were compared using a linear mixed effects model with group as a categorical variable and subject as a random effect | Mixed Models Analysis | Analyses are not adjusted for multiplicity. | 0.66 | Geometric mean ratio | 0.98 | 2-Sided | 90 | 0.91 | 1.06 | Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone. | Other | A difference in exposure was concluded if the 2-sided 90% CI of the geometric mean ratio excluded 1, which is standard in pharmacokinetic studies |
| Area under the curve was log-transformed and the values between groups were compared using a linear mixed effects model with group as a categorical variable and subject as a random effect | Mixed Models Analysis | Analyses are not adjusted for multiplicity. | <0.01 | Geometric mean ratio | 1.26 | 2-Sided | 90 | 1.17 | 1.36 | Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone. | Other | A difference in exposure was concluded if the 2-sided 90% CI of the geometric mean ratio excluded 1, which is standard in pharmacokinetic studies |
| Maximum concentration was log-transformed and the values between groups were compared using a linear mixed effects model with group as a categorical variable and subject as a random effect | Mixed Models Analysis | Analyses are not adjusted for multiplicity. | 0.07 | Geometric mean ratio | 1.11 | 2-Sided | 90 | 1.01 | 1.21 | Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone. | Other | A difference in exposure was concluded if the 2-sided 90% CI of the geometric mean ratio excluded 1, which is standard in pharmacokinetic studies |